Lecka-Czernik B reported that Aleglitazar, being developed by Roche Holding, is a dual agonist for PPARD and PPARA for the promising multiple treatment of hyperglycemia and dyslipidemia with T2DM patients [20]. The gene discussed is PPARA; the disease is metabolic syndrome.